Chen Liu, MD, PhD, Is Named Chair of Pathology
Chen Liu, MD, PhD, has been chosen to be the next chair of the Department of Pathology at Yale School of Medicine and chief of Pathology at Yale New Haven Hospital, effective March 1, 2020. He comes from Rutgers Biomedical and Health Sciences in New Jersey.
Researchers Identify Stem Cell Source of Key Process in Female Reproduction
Each month during women’s reproductive years, the uterus sheds and regenerates the tissue lining its walls in preparation for a pregnancy or the next cycle. The process behind this age-old and essential part of human reproduction is not well understood. But recent research led by Yale pathologist Wang Min identifies stem cells and a gene that contribute to this monthly event.
Yale enhances its cytometry capabilities
The methods and equipment used to probe cellular questions are rapidly advancing—including, at Yale, through the addition in 2014 of CyTOF, or Cytometry Time-Of-Flight, and this past June of the CyTOF Imaging Mass Cytometer (IMC), which greatly expands Yale's ability to examine specimens that are analyzed both for clinical diagnosis and for basic research.Source: Medicine@Yale
Yale doctor creates new weapons to kill cancer
The battle against cancer is increasingly being fought on the genetic level, and Dr. Samuel Katz is aiding the body’s immune system by creating safer, more effective weapons. His research is focused on treating cancers of the blood, such as multiple myeloma, Hodgkin’s lymphoma and acute myeloid leukemia, but his technique could eventually be used against solid tumors as well, including cancers of the breast, ovary, pancreas and colon. Most gene therapy uses genetically modified DNA in the body’s T lymphocytes — a type of white blood cell that is an integral part of the body’s immune system — to find, attack and kill cancer cells.Source: New Haven Register
Zika-related nerve damage caused by immune response to the virus
The immune system’s response to the Zika virus, rather than the virus itself, may be responsible for nerve-related complications of infection, according to a Yale study. This insight could lead to new ways of treating patients with Zika-related complications, such as Guillain-Barré syndrome, the researchers said.
Promising Yale cancer research supported by Stamford based non-profit leading charge in gene therapy studies
Support from ACGT has Dr. Samuel Katz at Yale School of Medicine refining the current research. He is reprogramming cells, with RNA, the genetic material that delivers the message, to destroy the cancerous ones — acting as soldiers in battle, if you will. “We give them the message,” says Dr. Katz, “and then the message goes away, and when the soldier is done with his job he returns back to normal.” If successful, this approach will make safer and stronger cells – a super-soldier that reintegrates into society when the war is won.Source: WTNH News Channel 8
Study uncovers markers for severe form of multiple sclerosis
Scientists have uncovered two closely related cytokines — molecules involved in cell communication and movement — that may explain why some people develop progressive multiple sclerosis (MS), the most severe form of the disease. The findings, authored by researchers at Yale University, Oregon Health & Science University, and the University of California point the way toward developing a novel treatment to prevent progressive forms of the disease.
Cancer diagnosis? Why calling your pathologist might be a good idea
Through modern technology, today’s patient has access to so much information, yet we’re sometimes leaving out the most traditional source of knowledge: talking to your doctor. Patients should know that they might benefit from talking to their pathologist.Source: Healthy Debate
Limiting lung cancer’s spread and growth in the brain
More people die of lung cancer each year than breast, colon, and prostate cancers combined. One particularly lethal form of the disease is lung adenocarcinoma or LUAD, which afflicts both smokers and non-smokers. In many patients diagnosed with LUAD, tumors cells have already spread to the brain, leading to decreased quality of life and low survival rates. A Yale Cancer Center research team conducted a study to determine how those tumor cells manage to grow outside the lungs.
Researchers at Yale have taken steps toward a ‘completely unexpected’ new way to treat brain cancer
Researchers at Yale think they've come up with a new way to treat a certain kind of brain tumor using a drug that's already been approved by the FDA. In a study published Wednesday in the journal Science Translational Medicine, the researchers outline a hypothesis for using the drug to tackle brain cancer. Thing is, the hypothesis they put forward is the exact opposite of the one other scientists, as well as several drug companies including Agios Pharmaceuticals, had previously been working with. The drug they discuss, called a PARP inhibitor, blocks a protein our cells use to repair DNA and kill off tumors. In certain kinds of cancer, that repair system is broken, which allows cancer cells to thrive.Source: Yahoo Finance
Yale scientists identify key defect in brain tumor cells
In a new study, Yale Cancer Center researchers identified a novel genetic defect that prevents brain tumor cells from repairing damaged DNA. They found that the defect is highly sensitive to an existing FDA-approved drug used to treat ovarian cancer — a discovery that challenges current practice for treatment of brain tumors and other cancers with the same genetic defect, said the scientists.